·284·参考文献1KalidasM，KantarjianH，TalpazMChronic myelogenous leuke— mia．JAMA，2001；286：895—8982张之南，血液病诊断及疗效标准．第三版，北京：科学出版社．2007：134—1383钱思轩，李建勇，潘金兰等．荧光原位杂交技术在异性间造血干细胞移植后Ph阳性白血病的检测意义．中华内科杂志，2006；45：234—2364MorelF，KaC，LeBrisMJ，et a1．Deletion ofthe5’ABL region inPhiladelphia chromosome positive chronic myeloid leukemia： frequency，origin and prognosis．LeukLymphoma，2003；44：1333—Quintas-CardamaA，KantarjianH，TalpazM，et a1．Imatinib mesylate therapy may overcome the poor prognostic significance of中国实验血液学杂志JExpHematol2009；17(2) deletions of derivative chromosome9 in patients with chronic myelogenous leukemia．Blood，2005；105：2281—CohenN．Rozenfeld—GranotG．HardanI，et a1．Subgroup of patients withPhiladelphia—positive chronic myelogenous leukemia characterized by a deletion of9q proximal tOABL gene：expression profiling．resistance to interferon therapy，and poor prognosis．CancerGenetCytogenet，2001；128：114—1197HuntlyBJ，ReidAG，BenchAJ，et a1．Deletions of the derivative chromosome9 occur at the time of thePhiladelphia translocation and provide a powerful and independent prognostic factor in chronic myeloid leukemia．Blood，2001；98：1732—KolomietzE，A1一MaghmbiJ，BrennanS，et a1．Primary chromo。 somal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prog。 nosis．Blood，2001；97：3581—3588

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/qikandaodu/2021/0709/670.html